Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NanoMed-CKD

Financiado

Cerrado

Feasibility of mCura1 A kidney targeted nanomedicine that promotes self healing...

Feasibility of mCura1 A kidney targeted nanomedicine that promotes self healing of Chronic Kidney Disease with messenger RNA. Chronic Kidney Disease (CKD) is a little-known disease, but does affect 10-13% of the population in Europe and constitutes the 9th cause of death. Hallmark of this disease is loss of kidney function, leading to the progressive los... ver más

31/05/2019

MERCURNA BV

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

MERCURNA BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-05-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

MERCURNA BV

50.00K€ | Lider

VENCO ELECTRONICA

1.03M€ | Participante

Proyectos interesantes

KIDNEW

Medical Technol...

Nanotechnology

3M€ Cerrado

SAF2017-92001-EXP

Medical Technol...

Nanotechnology

67K€ Cerrado

FJC2020-043505-I

Medical Technol...

Biomedical Imag...

53K€ Cerrado

PTQ-13-06001

Medical Technol...

Nanotechnology

84K€ Cerrado

PID2020-119087RB-I00

Medical Technol...

Nanotechnology

198K€ Cerrado

NEW DEAL

Medical Technol...

Nanotechnology

6M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 6 meses Fecha Inicio: 2018-11-15
Fecha Fin: 2019-05-31

Líder del proyecto

MERCURNA BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Chronic Kidney Disease (CKD) is a little-known disease, but does affect 10-13% of the population in Europe and constitutes the 9th cause of death. Hallmark of this disease is loss of kidney function, leading to the progressive loss of the ability to clear metabolic waste and produce kidney-specific hormones. The consequences affect the entire body (heart attacks, anaemia,osteoporosis and cognitive decline) and ultimately become life-threatening. Management of these consequences with currently available drugs or dialysis does not stop, but merely slows the progression. The only alternative is kidney-transplantation, which is a very limited solution due to a donor-shortage and the relatively short survival of the transplant. In addition, these treatments frequently cause severe side-effects, resulting in a problematic decrease in quality of life. The chronic nature of the disease, the high number of patients and the high number of drugs per patient, together place a large (financial) burden on the healthcare system, consuming 4-17% of the European healthcare budgets. In pursuit of the first curative treatment for CKD, Mercurna is developing a kidney-targeted nanomedicine, mCura1. The unique selling point of mCura1 is the combination of the enhanced safety provided by kidney-targeting and the efficacy provided by mRNAbased therapeutics. Mercurna has booked very promising results in pre-clinical studies accumulating in several patent applications. In the NanoMed-CKD project, Mercurna will further develop its business plan to support the (clinical) development path to bring this groundbreaking therapy from lab to clinic to market.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores